

**Daniel M. Bradbury**  
BioBrit, LLC  
2223 Avenida de la Playa  
Suite 108  
La Jolla CA 92037

Email: [dan@biobrit.com](mailto:dan@biobrit.com)  
Mobile: (858) 344-6124  
Website: [www.biobrit.com](http://www.biobrit.com)

---

Life sciences executive with over 40 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market, and maximize shareholder value.

---

## **EXPERIENCE**

### **Managing Member**

**BioBrit, LLC – [www.biobrit.com](http://www.biobrit.com)**

**September 2012 – present**

- Life Sciences Consulting and Investment Firm
- Year End 2025 IRR 18.7%, TVPI 2.0x

### **Chairman and Co-Founder**

**Equillum, Inc. (2017 – present) / [www.equilliumbio.com](http://www.equilliumbio.com) (NASDAQ: EQ)**

**October 2025 – present**

- Public US Biopharmaceutical Company focused on developing first-in-class therapies to treat severe autoimmune disorders with high unmet medical need

### **Executive Chairman and Co-Founder**

**Equillum, Inc.**

**January 2020 – October 2025**

### **Chief Executive Officer, Chairman and Co-Founder**

**Equillum, Inc.**

**May 2017 – January 2020**

- Led company in \$72 million initial public offering

### **President and Chief Executive Officer and Director**

**Amylin Pharmaceuticals, Inc. (1994-2012) / (NASDAQ: AMLN)**

**March 2007 – August 2012**

- Public US Biopharmaceutical Company focused on developing medicines for the treatment of metabolic diseases – diabetes, obesity and lipodystrophy
- Led process resulting in the sale of Amylin to Bristol-Myers Squibb for \$7 billion
- Led company through a highly complex regulatory process and gained approval of and launched BYDUREON® in USA
- Managed company to positive operating cash flow for the first time in its 24-year history in 2011
- Sued and subsequently settled with Eli Lilly resulting in the return of global rights to exenatide
- Managed company through a complicated proxy challenge from Carl Icahn and Eastbourne Capital
- Drove a global development and commercialization agreement with Takeda for obesity assets
- Restructured Amylin after an FDA safety alert on BYETTA led to a significant decline in revenues

### **President and Chief Operating Officer and Director**

**Amylin Pharmaceuticals, Inc.**

**June 2006 – March 2007**

- Responsible to CEO for Research and Development, Regulatory Affairs, Corporate Strategy, Alliance Management and Business Development
- Integral in financial strategy involving raising >\$2 billion through sale of equity and debt since 1998

**Chief Operating Officer**

**June 2003 – June 2006**

**Amylin Pharmaceuticals, Inc.**

- Responsible to CEO for Research and Development, Regulatory Affairs and Business Development
- Gained approval of BYETTA® and SYMLIN® in US and BYETTA® in Europe
- BYETTA® approved in over 90 countries

**Executive Vice President**

**June 2000 – June 2003**

**Amylin Pharmaceuticals, Inc.**

- Responsible to CEO for Finance, Legal, Clinical Research, Discovery, Business Development, Strategic Planning, European Operations, Investor Relations and Corporate Communications
- Instrumental in the negotiation of the \$465M exenatide global development and commercialization agreement with Eli Lilly & Co.
- Lead executive responsible for finance strategy and resource allocation

**Senior Vice President, Corporate Development**

**March 1998 – June 2000**

**Amylin Pharmaceuticals, Inc.**

- Responsible to CEO for Business Development, Strategic Planning, Investor Relations, Corporate Communications and Marketing
- Negotiated sale of Product Development Division to Magellan Labs (now Cardinal)
- Negotiated feasibility and development collaborations with multiple drug delivery companies
- In-licensed multiple patents to enhance patent portfolio of development programs

**Vice President, Marketing**

**June 1995 – March 1998**

**Amylin Pharmaceuticals, Inc.**

- Commercial Liaison Officer Amylin/Johnson & Johnson collaboration and Co-chair Joint Commercialization Committee
- Successfully managed global coordination of SYMLIN™ commercialization planning with Johnson & Johnson commercial teams
- Built global Strategic Marketing Team with national expertise in US and major European markets - team located in San Diego, New Jersey, Oxford (UK), Paris (France) and Dusseldorf (Germany)
- Provided commercial assessment of in-license candidates – AC2993 (exendin-4) & HMR deals

**Director, Marketing Amylin Pharmaceuticals**

**July 1994 – June 1995**

**Amylin Europe, UK**

- Presented market opportunity for Amylin agonist program to multiple pharmaceutical companies as part of Corporate partnership strategy
- Negotiated commercialization relationship in worldwide SYMLIN™ collaboration agreement with Johnson & Johnson
- Implemented worldwide SYMLIN™ medical communications program

**Assoc. Director Anti-Infectives, Worldwide Strategic Product Development**

**February 1991 – July 1994**

**SmithKline Beecham Pharmaceuticals, UK (1984-1994) / (LSE: GSK)**

- Global Pharmaceutical Company focused on developing and commercializing medicines and vaccines
- Focused R&D teams on the key competitive issues relating to the Global antiviral market and negotiated a revised development plan leading to accelerated FAMVIR™ launches
- Initiated DENAVIR™ OTC switch strategy
- Provided strategic and tactical support for successful UK FAMVIR™ launch in January 1994 and US FAMVIR™ launch in July 1994 (FAMVIR™ sold by SB to Novartis for \$1.63BN in August 2000)
- Authored Global Anti-Infectives/Vaccines Therapeutic 15-year strategic plan

**Product Group Manager, International Area Marketing**  
**SmithKline Beecham Pharmaceuticals, UK**

**June 1990 – February 1991**

- Successfully initiated Area Marketing program to establish SB in the hospital injectable antibiotics market, e.g. Launched TIMENTIN™ & IV AUGMENTIN™ in Indonesia, relaunched IV AUGMENTIN™ in Saudi Arabia and launched TIMENTIN™ & IV AUGMENTIN™ in Mexico

**Area Manager Gulf States, International Division**  
**Beecham Pharmaceuticals, Sharjah, UAE**

**December 1988 – June 1990**

- Managed Area Office. Responsible for two sales forces and six distributors across five markets (Bahrain, Kuwait, Oman, Qatar, UAE). Responsible for Area Profit - 1989 Area Gross Profit growth rate 23%
- Managed area integration of Beecham and SK&F teams

**Marketing Supervisor Middle East, International Division**  
**Beecham Pharmaceuticals, UK**

**October 1987 – December 1988**

- Effectively coordinated Middle East promotional activity and conducted numerous representative training courses for Middle East AUGMENTIN™ and BACTROBAN™ launches

**International Trainee, International Division**  
**Beecham Pharmaceuticals, UK**

**September 1984 – October 1987**

- Marketing Executive, Marketing and Services Department
- Medical Representative, Beecham Research Laboratories, UK Division
- Area Assistant, International Division

**Pre-registration Pharmacist**

**Glaxo Group Research & Northwick Park Hospital, UK**

**September 1983 – September 1984**

**EDUCATION**

**1983 Nottingham University, UK**

- Bachelor of Pharmacy (Hons)
- Registered UK Pharmacist 1984 – 2011

**1985 University of West London, UK**

- Postgraduate Diploma in Management Studies (DMS)
- Diploma of the Chartered Institute of Marketing (DCIM)

**1994 INSEAD, European Institute of Business Administration, France**

- International Executive Program

**2004 University of California, Los Angeles**

- Director Certification Program

**HONORS AND AWARDS**

- American Diabetes Association's Father of the Year – San Diego Chapter (2011)
- E&Y Entrepreneur of the Year Finalist (2012)
- Corporate Directors Forum Director of the Year Award – Enhancing Economic Value (2012)
- PharmaVOICE 100 Most Inspiring People (2019)
- Corporate Directors Forum Director of the Year award – Lifetime Achievement in Corporate Governance (2023)

## **BOARDS AND COMMITTEES**

### **Public Boards:**

#### **illumina, Inc. (2004 – 2017) / [www.illumina.com](http://www.illumina.com) (NASDAQ: ILMN)**

- Independent Director
- Audit Committee (Chair: 2005 – 2010)
- Compensation Committee
- Nominating and Governance Committee (Chair: 2013 – 2017)

#### **Novacea, Inc. (2005 – 2009) / (NASDAQ: NOVC) – merged with Transcept Pharmaceuticals Inc.**

- Independent Director
- Compensation Committee (Chair)
- Nominating and Corporate Governance Committee

#### **Amylin Pharmaceuticals, Inc. (2006 – 2012) / (NASDAQ: AMLN)**

##### **Acquired by Bristol-Myers Squibb for \$7 billion**

- Director
- Finance and Risk Committee

#### **Geron Corporation (2012 – 2019) / [www.geron.com](http://www.geron.com) (NASDAQ: GERN)**

- Independent Director
- Audit Committee (2012 – 2019)
- Nominating and Governance Committee (2015 – 2019)

#### **Corcept Therapeutics, Inc. (2012 – 2019) / [www.corcept.com](http://www.corcept.com) (NASDAQ: CORT)**

- Independent Director
- Compensation Committee (2013 – 2019)
- Nominating and Governance Committee (2016 – 2019)

#### **BioMed Realty Trust, Inc. (2013 – 2016) / [www.biomedrealty.com](http://www.biomedrealty.com) (NYSE: BMR)**

##### **Acquired by Blackstone Real Estate Partners VIII L.P. for \$8 billion**

- Lead Independent Director
- Compensation Committee
- Nominating and Governance Committee (Chair)

#### **Biocon Limited (2013 – 2022) / [www.biocon.com](http://www.biocon.com) (NSE: BIOCON)**

- Independent Director
- Audit and Risk Committee (2013 – 2022)
- Stakeholders Relationship (Chair: 2015 – 2022)
- Nomination and Remuneration Committee (2013 – 2015)

#### **Syngene International Limited (2015 – 2016) / <http://www.syngeneintl.com> (NSE: SYNGENE)**

- Independent Director
- Nomination and Remuneration Committee

#### **Intercept Pharmaceuticals, Inc. (2016 – 2023) / [www.interceptpharma.com](http://www.interceptpharma.com) (NASDAQ: ICPT)**

##### **Acquired by Alfasigma S.p.A. for \$800 million**

- Independent Director
- Audit Committee (2016 – 2023)
- Nominating and Governance Committee (2016 – 2023)

**Equillum, Inc. (2018 – present) / [www.equilliumbio.com](http://www.equilliumbio.com) (NASDAQ: EQ)**

- Chairman of the Board

**Castle Biosciences, Inc. (2019 – present) / [www.castlebiosciences.com](http://www.castlebiosciences.com) (NASDAQ: CSTL)**

- Chairman of the Board

**Panacea Acquisition Corporation (2020 – 2021) / (NYSE: PANA.U)**

**Combined with Nuvation Bio Inc. [www.nuvationbio.com](http://www.nuvationbio.com)**

- Chairman of the Board
- Audit Committee (Chair)

**Vivani Medical, Inc. (2024 – present) / [www.vivani.com](http://www.vivani.com) (NASDAQ: VANI)**

- Independent Director
- Audit Committee

Private Boards:

**Peninsula Pharmaceuticals, Inc. (2003 – 2005)**

**Acquired by J&J for \$245 million**

- Director

**Cerexa, Inc. (2005 – 2006)**

**Acquired by Forest Laboratories for \$480 million**

- Director
- Compensation Committee (Chair)

**Castle Biosciences, Inc. (2012 – 2019) / [www.castlebiosciences.com](http://www.castlebiosciences.com)**

- Chairman of the Board
- Compensation Committee (2012 – 2019)

**Microdermis Corporation (2013 – 2018) / [www.microdermis.com](http://www.microdermis.com)**

- Director
- Audit Committee (Chair)

**Freedom Meditech (2013 – 2017) / [www.freedom-meditech.com](http://www.freedom-meditech.com)**

- Chairman of the Board

**DiaVacs, Inc. (2013 – 2019) / [www.diavac.com](http://www.diavac.com)**

- Chairman of the Board

**ProSciento, Inc. (2013 – present) / [www.prosciento.com](http://www.prosciento.com)**

- Director
- Compensation Committee (Chair)

**Troia Therapeutics, Inc. (2014 – 2017)**

- Chairman of the Board

**Liquid Grids, Inc. (2014 – 2021)**

**Acquired by Femtec Health [www.femtechealth.com](http://www.femtechealth.com) for \$20 million**

- Chairman of the Board

**Sensulin, LLC (2014 – present) / [www.sensulin.com](http://www.sensulin.com)**

- Chairman of the Board

**Renova Therapeutics (2014 – 2021) / [www.renovatherapeutics.com](http://www.renovatherapeutics.com)**

- Director
- Compensation Committee (Chair)

**SiteOne Therapeutics (2014-2024) / [www.siteonetherapeutics.com](http://www.siteonetherapeutics.com)**

- Observer

**Thesan Pharmaceuticals, Inc. (2016 – 2017) / [www.thesanpharma.com](http://www.thesanpharma.com)**

- Chairman of the Board

**Equillium, Inc. (2017 – 2018) / [www.equilliumbio.com](http://www.equilliumbio.com)**

- Chairman of the Board

**NeuroVia, Inc. (2017 – 2019) / [www.neurovia-inc.com](http://www.neurovia-inc.com)**

- Chairman of the Board

**Biolinq, Inc. (2017 – present) / [www.biolinq.me](http://www.biolinq.me)**

- Chairman of the Board

**DelNova, Inc. (2018 – present) / [www.delnova.net](http://www.delnova.net)**

- Chairman of the Board

**Biocon Biologics Limited (2018 – present) / <http://www.bioconbiologics.com/>**

- Director
- Audit Committee
- Risk Management Committee
- Nomination and Remuneration Committee

**IQHQ (2019 – 2024) [www.ighqreit.com](http://www.ighqreit.com)**

- Director
- Audit Committee
- Compensation Committee (Chair)

**Synedgen, Inc. (2019 – 2024) / [www.synedgen.com](http://www.synedgen.com)**

- Director

**Alume Biosciences, Inc. (2020 – present) / [www.alumbiosciences.com](http://www.alumbiosciences.com)**

- Executive Chairman of the Board (2025 – present)
- Director (2020 – 2025)

**AltheaDx, Inc. (2020 – 2022) / <https://www.altheadx.com/>**

Acquired by Castle Biosciences [www.castlebiosciences.com](http://www.castlebiosciences.com) for \$65 million plus up to \$75 million in milestone payments

- Director

**Neuralace Medical Inc. (2020-present) / [www.neuralacemedical.com](http://www.neuralacemedical.com)**

- Observer

**Amplo Biotechnology, Inc. (2021 – present) / [www.amplobiotechnology.com](http://www.amplobiotechnology.com)**

- Executive Chairman of the Board

**Abilita Bio, Inc. (2022 – present) / [www.abilitabio.com](http://www.abilitabio.com)**

- Director

**Persephone Biosciences (2023 – present) / [www.persephonebiosciences.com](http://www.persephonebiosciences.com)**

- Chairman of the Board

**Minutia (2024 – present) / [www.minutia.co](http://www.minutia.co)**

- Chairman of the Board

**Tavo Biotherapeutics (2025 – present) / [www.tavobio.com](http://www.tavobio.com)**

- Chairman of the Board

Advisory Boards:

**EGS PARTNERS \$100mm Biomedical Investment Fund Advisory Board (2000 – 2009)**

- Advisor

**RAND Health Board of Advisors (2008 – 2013) / [www.rand.org](http://www.rand.org)**

- Advisor

**University of Miami's Innovation Corporate Advisory Council (2009 – 2014)**

- Advisor

**Patricia Industries (a part of Investor AB) (2010 – 2017) / <http://www.patriciaindustries.com>**

*\*formerly Investor Growth Capital*

- Advisor

**BioMed Ventures Advisory Committee (2011 – 2019) / [www.biomedrealty.com](http://www.biomedrealty.com)**

- Advisor

**AmideBio LLC Advisory Board (2013 – present) / [www.amidebio.com](http://www.amidebio.com)**

- Advisor

**Pharming Group N.V. Commercial Advisory Board (2017 – 2022) / [www.pharming.com](http://www.pharming.com)**

- Chairman of the Board

**ProLynx, LLC Advisory Board (2017 – present) / [www.prolynxllc.com](http://www.prolynxllc.com)**

- Advisor

**Arctic Aurora Life Science Advisory Board (2017 – 2019) / <https://www.arctic.com/afm/department/our-funds/#arctic-aurora-lifescience>**

- Advisor

**Nano Precision Medical/Vivani Advisory Board (2017 – 2024) / [www.vivani.com](http://www.vivani.com)**

- Advisor

**Minutia (2020 – 2024) / [www.minutia.co](http://www.minutia.co)**

- Advisor

**Persephone Biosciences (2018 – 2023) / [www.persephonebiosciences.com](http://www.persephonebiosciences.com)**

- Advisor

**IMIDomics (2021 – Present) / [www.imidomics.com](http://www.imidomics.com)**

- Advisor

**Abilita Bio (2021 – 2022) / [www.abilitabio.com](http://www.abilitabio.com)**

- Advisor

**AXA Investment Managers UK, Global Health Private Equity Advisory Board (2022 – Present) / <https://alts.axa-in.com/investment-expertise/private-equity-and-infrastructure/healthcare>**

- Advisor

**Medical Excellence Capital Advisory Board (2022 – Present) / [www.medexcelcap.com](http://www.medexcelcap.com)**

- Advisor

**RNAV8 Bio (2024 – Present) / [www.rnav8bio.com](http://www.rnav8bio.com)**

- Advisor

**Intrinsic Medicine (2024 – Present) / [www.intrinsicmedicine.com](http://www.intrinsicmedicine.com)**

- Advisor

**Navega Therapeutics (2024 – Present) / [www.navegatx.com](http://www.navegatx.com)**

- Advisor

**BRT Biotechnologies (2024 – Present) / [www.brtbio.com](http://www.brtbio.com)**

- Advisor

**XenoMet (2025 – Present) / website pending**

- Advisor

**Aria Therapeutics, Inc. (2025 – Present) / website pending**

- Advisor

**NeuraClick (2025 – Present) / [www.neuraclickttx.com](http://www.neuraclickttx.com)**

- Advisor

**TIXiMed (2025 – Present) / [www.tiximed.com](http://www.tiximed.com)**

- Advisor

**Courage Therapeutics (2025 – Present) / [www.couragetx.com](http://www.couragetx.com)**

- Advisor

Non-Profit Boards:

**Keck Graduate Institute (a Claremont College) (2006 – present) / [www.kgi.edu](http://www.kgi.edu)**

- Member of the Board of Trustees
- Executive Committee (2023 – present)
- Budget and Finance Committee (2007 – 2015)
- Audit and Risk Committee (2008 – 2012 / Chair 2015 – 2023, 2024 - present)
- Advancement Committee (2006 – 2009 / 2012 – 2015)
- Chairman of the KGI Advisory Council (2003 – 2006)

**UCSD Rady School of Management (2006 – present) / [www.rady.ucsd.edu](http://www.rady.ucsd.edu)**

- Member of the Dean's Advisory Council

**Pharmaceutical Research and Manufacturers of America (2007 – 2010) / [www.phrma.org](http://www.phrma.org)**

- Director

**BIOCOM (2007 – 2012) / [www.biocom.org](http://www.biocom.org)**

- Director (Chair 2010)

**Riecken Community Libraries (2013 – present) / [www.riecken.org](http://www.riecken.org)**

- Director

**ADCY5.org (2016 – present) / [www.ADCY5.org](http://www.ADCY5.org)**

- Chairman of the Board

**The San Diego Exploratory Foundation (SDEF) (2017 – 2019) / <https://awbgsandiego.com/about/>**

- Member of the World Beach Games 2019 Committee